CN117042770A - 用于患有高脂血症或混合性血脂异常的他汀类不耐受患者的奥比塞曲匹与依折麦布的组合治疗 - Google Patents

用于患有高脂血症或混合性血脂异常的他汀类不耐受患者的奥比塞曲匹与依折麦布的组合治疗 Download PDF

Info

Publication number
CN117042770A
CN117042770A CN202280015230.8A CN202280015230A CN117042770A CN 117042770 A CN117042770 A CN 117042770A CN 202280015230 A CN202280015230 A CN 202280015230A CN 117042770 A CN117042770 A CN 117042770A
Authority
CN
China
Prior art keywords
ezetimibe
combination
ldl
day
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280015230.8A
Other languages
English (en)
Chinese (zh)
Inventor
约翰尼斯·雅各布·彼得·卡斯特林
马克·迪特马施
迈克尔·哈维·戴维森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NewAmsterdam Pharma NV
Original Assignee
NewAmsterdam Pharma NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NewAmsterdam Pharma NV filed Critical NewAmsterdam Pharma NV
Publication of CN117042770A publication Critical patent/CN117042770A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CN202280015230.8A 2021-02-18 2022-02-18 用于患有高脂血症或混合性血脂异常的他汀类不耐受患者的奥比塞曲匹与依折麦布的组合治疗 Pending CN117042770A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NLPCT/NL2021/050109 2021-02-18
NL2021050109 2021-02-18
PCT/NL2022/050083 WO2022177428A1 (en) 2021-02-18 2022-02-18 Combination therapy of obicetrapib and ezetimibe for use in statin intolerant patients suffering from hyperlipidemia or mixed dyslipidaemia

Publications (1)

Publication Number Publication Date
CN117042770A true CN117042770A (zh) 2023-11-10

Family

ID=74844966

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280015230.8A Pending CN117042770A (zh) 2021-02-18 2022-02-18 用于患有高脂血症或混合性血脂异常的他汀类不耐受患者的奥比塞曲匹与依折麦布的组合治疗

Country Status (11)

Country Link
US (1) US20240189311A1 (cg-RX-API-DMAC7.html)
EP (1) EP4294387A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024507810A (cg-RX-API-DMAC7.html)
KR (1) KR20230159380A (cg-RX-API-DMAC7.html)
CN (1) CN117042770A (cg-RX-API-DMAC7.html)
AU (1) AU2022223224A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023016682A2 (cg-RX-API-DMAC7.html)
CA (1) CA3210033A1 (cg-RX-API-DMAC7.html)
IL (1) IL304544A (cg-RX-API-DMAC7.html)
MX (1) MX2023009613A (cg-RX-API-DMAC7.html)
WO (1) WO2022177428A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12006305B2 (en) 2022-07-05 2024-06-11 Newamsterdam Pharma B.V. Salts of obicetrapib and processes for their manufacture and intermediates thereof
EP4661865A1 (en) * 2023-02-07 2025-12-17 NewAmsterdam Pharma B.V. Obicetrapib and ezetimibe combination treatment and fixed dose pharmaceutical compositions
WO2025146262A1 (en) * 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Obicetrapib for use in the treatment of hemoglobinopathies
WO2025146445A1 (en) * 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Pharmaceutical compositions of obicetrapib and ezetimibe
WO2025147235A1 (en) * 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Fixed dose combination composition of obicetrapib and ezetimibe
WO2025146446A1 (en) * 2024-01-03 2025-07-10 Newamsterdam Pharma B.V. Pharmaceutical compositions of obicetrapib

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1938314A (zh) * 2004-04-02 2007-03-28 田边制药株式会社 四氢喹啉衍生物及其制备方法
CN104382896A (zh) * 2014-11-04 2015-03-04 万全万特制药江苏有限公司 含有依折麦布和辛伐他汀的药物组合物
CN106232121A (zh) * 2014-02-05 2016-12-14 田边三菱制药株式会社 用于治疗或预防心血管疾病的胆固醇酯转移蛋白(cetp)抑制剂和含所述抑制剂的药物组合物
WO2017023166A1 (en) * 2015-08-04 2017-02-09 Dezima Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and a cholesterol absorption inhibitor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12006305B2 (en) * 2022-07-05 2024-06-11 Newamsterdam Pharma B.V. Salts of obicetrapib and processes for their manufacture and intermediates thereof
IL318925A (en) * 2022-08-22 2025-04-01 Newamsterdam Pharma B V Combination therapy with ovistrefib and ezetimibe and fixed-dose pharmaceutical preparations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1938314A (zh) * 2004-04-02 2007-03-28 田边制药株式会社 四氢喹啉衍生物及其制备方法
CN106232121A (zh) * 2014-02-05 2016-12-14 田边三菱制药株式会社 用于治疗或预防心血管疾病的胆固醇酯转移蛋白(cetp)抑制剂和含所述抑制剂的药物组合物
CN104382896A (zh) * 2014-11-04 2015-03-04 万全万特制药江苏有限公司 含有依折麦布和辛伐他汀的药物组合物
WO2017023166A1 (en) * 2015-08-04 2017-02-09 Dezima Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and a cholesterol absorption inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHIRYA RASHID等: "Lower LDL is better – can this be achieved with CETP inhibition therapy?", EXPERT REVIEW OF CARDIOVASCULAR THERAPY, vol. 18, no. 1, 23 January 2020 (2020-01-23), pages 3 - 4 *

Also Published As

Publication number Publication date
JP2024507810A (ja) 2024-02-21
KR20230159380A (ko) 2023-11-21
CA3210033A1 (en) 2022-08-25
WO2022177428A1 (en) 2022-08-25
MX2023009613A (es) 2023-11-09
AU2022223224A1 (en) 2023-08-24
IL304544A (en) 2023-09-01
US20240189311A1 (en) 2024-06-13
BR112023016682A2 (pt) 2023-11-14
EP4294387A1 (en) 2023-12-27

Similar Documents

Publication Publication Date Title
US20240189311A1 (en) Combination Therapy of Obicetrapib and Ezetimibe for Use in Statin Intolerant Patients Suffering from Hyperlipidemia or Mixed Dyslipidaemia
US6982157B1 (en) Drug combinations comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methylsulfonyl)amino] pyrimidin-5-yl] (3r,5s) -3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3A4
MX2007015677A (es) Formulacion de 1-[(3-hidroxi-adamant-1-ilamino)-acetil]-pirrolidin -2(s)-carbonitrilo de liberacion modificada.
US20200113882A1 (en) Use of 4-Aminopyridine to Improve Neuro-Cognitive and/or Neuro-Psychiatric Impairment in Patients with Demyelinating and Other Nervous System Conditions
JP2006520810A (ja) S−[2−([[1−(2−エチルブチル)シクロヘキシル]カルボニル]アミノ)フェニル]2−メチルプロパンチオエートの経口吸収性を増加させる方法
JP2025522785A (ja) 多発性硬化症及び重症筋無力症に対する治療用チロシンキナーゼ阻害剤
JP2025516634A (ja) ミエリンオリゴデンドロサイト糖タンパク質抗体疾患(mogad)の治療における使用のためのブルトンチロシンキナーゼ阻害剤
EP1272219B1 (en) New combination of a betablocker and a cholesterol-lowering agent
JP7524167B2 (ja) Iv型コラーゲン疾患の処置のためのビフェニルスルホンアミド化合物
AU2014332200B2 (en) HIV treatment formulation of atazanavir and cobicistat
JP2025534632A (ja) 多発性硬化症治療のためのチロシンキナーゼ阻害剤
TW202002981A (zh) 藥物組成物與包含膽固醇酯轉移蛋白抑制劑和HMG CoA還原酶抑制劑的治療組合
TW202547505A (zh) 包含azd0780之醫藥組合物
WO2021142062A1 (en) Fumarate ester dosage forms with enhanced gastrointestinal tolerability
CZ20024181A3 (cs) Farmaceutické prostředky obsahující betablokátor
SK11092001A3 (sk) Kombinácia vzájomne nereagujúcich liečiv obsahujúca inhibítor hmg-coa reduktázy a inhibítor, induktor alebo substrát p450 izoenzýmu 3a4
JP2023520021A (ja) チロシンキナーゼ阻害剤の小児用製剤
HUE030936T2 (en) Use of fenofibrate or a derivative thereof for treating diabetic retinopathy
WO2020053219A1 (en) Treatment of psoriasis
WO2020053218A1 (en) Treatment of psoriasis
HK1051325B (en) New combination of a betablocker and a cholesterol-lowering agent
ZA200105838B (en) Drug combinations comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino] pyrimidin-5-YL] (3R,5S) -3,5-dihydroxyhept-6-enoic acid and an inhibitor inducer or substrate of P450 isoenzyme 3A4.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination